147 related articles for article (PubMed ID: 26448941)
1. Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy.
Popovtzer A; Sarfaty M; Limon D; Marshack G; Perlow E; Dvir A; Soussan-Gutman L; Stemmer SM
Biomed Res Int; 2015; 2015():614845. PubMed ID: 26448941
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
4. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
Haddad R; Colevas AD; Krane JF; Cooper D; Glisson B; Amrein PC; Weeks L; Costello R; Posner M
Oral Oncol; 2003 Oct; 39(7):724-7. PubMed ID: 12907212
[TBL] [Abstract][Full Text] [Related]
5. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
Liu H; Du L; Wang R; Wei C; Liu B; Zhu L; Liu P; Liu Q; Li J; Lu SL; Xiao J
Oncotarget; 2015 May; 6(13):11477-91. PubMed ID: 25909167
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
7. Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes.
Wu HM; Ren GX; Wang LZ; Zhang CY; Chen WT; Guo W
Mol Med Rep; 2012 Aug; 6(2):271-4. PubMed ID: 22580922
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
9. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
Oral Oncol; 2012 Oct; 48(10):948-957. PubMed ID: 22698431
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
13. Breast- and salivary gland-derived adenoid cystic carcinomas: potential post-transcriptional divergencies. A pilot study based on miRNA expression profiling of four cases and review of the potential relevance of the findings.
Kiss O; Tőkés AM; Spisák S; Szilágyi A; Lippai N; Székely B; Szász AM; Kulka J
Pathol Oncol Res; 2015 Jan; 21(1):29-44. PubMed ID: 25240490
[TBL] [Abstract][Full Text] [Related]
14. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma.
Wang C; Li T; Yan F; Cai W; Zheng J; Jiang X; Sun J
Biomed Pharmacother; 2018 Sep; 105():1054-1061. PubMed ID: 30021341
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of nucleophosmin expression inhibited proliferation and induced apoptosis in salivary gland adenoid cystic carcinoma.
Li S; Zhang X; Zhou Z; Huang Z; Liu L; Huang Z
J Oral Pathol Med; 2017 Mar; 46(3):175-181. PubMed ID: 27501253
[TBL] [Abstract][Full Text] [Related]
16. Salivary gland cancers: biology and molecular targets for therapy.
Bell D; Hanna EY
Curr Oncol Rep; 2012 Apr; 14(2):166-74. PubMed ID: 22246609
[TBL] [Abstract][Full Text] [Related]
17. Expression of LC3, LAMP2, KEAP1 and NRF2 in Salivary Adenoid Cystic Carcinoma.
Huang CF; Deng WW; Zhang L; Zhang WF; Sun ZJ
Pathol Oncol Res; 2016 Jan; 22(1):109-14. PubMed ID: 26350055
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
[TBL] [Abstract][Full Text] [Related]
19. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Locati LD; Bossi P; Perrone F; Potepan P; Crippa F; Mariani L; Casieri P; Orsenigo M; Losa M; Bergamini C; Liberatoscioli C; Quattrone P; Calderone RG; Rinaldi G; Pilotti S; Licitra L
Oral Oncol; 2009 Jul; 45(7):574-8. PubMed ID: 18804410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
